glucagon
Baqsimi, Ogluo · ATC code H04AA01
- Key facts
- Active substance
- glucagon
- ATC code
- H04AA01
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- Baqsimi 3 mg nasal powder in single-dose container · Ogluo 0.5 mg solution for injection in pre-filled pen. / Ogluo 1 mg solution for injection in pre-filled pen. / Ogluo 0.5 mg solution for injection in pre-filled syringe.
- Marketing authorisation holder
- Amphastar France Pharmaceuticals, Strongbridge Dublin Limited
- Information as of
- 2026-10-27
Key facts
Glucagon is a hormone that raises blood glucose. As nasal powder (Baqsimi) or injection (Ogluo) it treats severe hypoglycaemia in people with diabetes mellitus.
What it is used for
- Baqsimi: severe hypoglycaemia in adults, adolescents and children aged 1 year and over with diabetes mellitus
- Ogluo: severe hypoglycaemia in adults, adolescents and children aged 2 years and over with diabetes mellitus
Dosing
- Baqsimi: 3 mg glucagon into one nostril; no need to inhale deeply.
- Ogluo, adults and adolescents (≥6 years): 1 mg subcutaneously.
- Ogluo, children ≥2 to <6 years: under 25 kg 0.5 mg, 25 kg or greater 1 mg subcutaneously.
- Ogluo: if no response within 15 minutes, an additional dose from a new device may be given.
- After response, give oral carbohydrate; call for medical help right away.
- No dose adjustment for age, renal or hepatic impairment.
Contraindications
- Hypersensitivity to the active substance or any excipient
- Phaeochromocytoma
Important warnings
- Phaeochromocytoma: glucagon may release catecholamines and sharply raise blood pressure
- Insulinoma: hypoglycaemia may follow an initial rise in glucose
- Ineffective when liver glycogen is depleted (starvation, adrenal insufficiency, alcohol abuse, chronic hypoglycaemia)
- Allergic reactions including anaphylactic shock may occur
Side effects
- Baqsimi: lacrimation increased (36%), upper respiratory tract irritation (34%), nausea (27%), headache (21%), vomiting (16%)
- Ogluo: nausea and vomiting very common; headache, tachycardia common
- Ogluo: injection site reactions
- Transient increases in blood pressure and heart rate
Interactions
- Insulin acts antagonistically to glucagon
- Indomethacin: glucagon may lose its glucose-raising effect or even produce hypoglycaemia
- Beta-blockers: greater, transient rise in pulse and blood pressure
- Warfarin: anticoagulant effect may increase
Pregnancy and breastfeeding
- Can be used during pregnancy; glucagon does not cross the placenta.
- Can be used during breast-feeding.
Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- BaqsimiAmphastar France Pharmaceuticals · EMEA/H/C/003848
- OgluoStrongbridge Dublin Limited · EMEA/H/C/005391
Source: European Medicines Agency (EMA), product information
Austria
- GlucagenNovo Nordisk Pharma Gmbh · 2 register entries
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Germany
- GlucagenNovo Nordisk Pharma Gmbh · 2 register entries
Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-28
Turkey
- Glucagen HypokitNOVO NORDİSK SAĞLIK ÜRÜNLERİ TİC LTD. ŞTİ. · 1 register entry
Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16
Brand names in 28 more European countries
- Belgium
- Glucagen
- Bulgaria
- Глюкаген Хипокит
- Croatia
- Glucagen Hypokit
- Cyprus
- Glucagen Hypokit
- Czechia
- Glucagen Hypokit
- Denmark
- Glucagen
- Estonia
- Glucagen Hypokit
- Finland
- Glucagen
- France
- Glucagen
- Greece
- Glucagen
- Hungary
- Glucagen Hypokit
- Iceland
- Baqsimi, Glucagen
- Ireland
- Glucagen Hypokit
- Italy
- Glucagen
- Latvia
- Glucagen Hypokit
- Liechtenstein
- Baqsimi
- Lithuania
- Glucagen Hypokit
- Luxembourg
- Glucagen
- Malta
- Glucagen
- Netherlands
- Glucagen Hypokit
- Norway
- Baqsimi, Glucagon
- Poland
- Glucagen Hypokit
- Portugal
- Glucagen
- Romania
- Glucagen Hypokit
- Slovakia
- Glucagen Hypokit
- Slovenia
- Glucagen Hypokit
- Spain
- Glucagen Hypokit
- Sweden
- Glucagon Novo Nordisk
EMA – Article 57 product data (EU/EEA), 2026-10-28
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Baqsimi – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/baqsimi-epar-product-information_en.pdf
- European Medicines Agency. Ogluo – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/ogluo-epar-product-information_en.pdf
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- EMA – Article 57 product data (EU/EEA), 2026-10-28. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
- TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85
Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.